Associated material
Tools
- Sign up for article alerts
- Download references
- Download XML
- Email to a friend
- Order reprints
- Post a comment
Citeulike
Connotea
Del.icio.us
Facebook
Mendeley
Twitter
Angiotensins and Alzheimer's disease: a bench to bedside overview
-
Correspondence: Patrick G Kehoe Patrick.Kehoe@bristol.ac.uk
Dementia Research Group, Institute of Clinical Neurosciences, Department of Clinical Science at North Bristol, University of Bristol, Frenchay Hospital, Bristol BS16 1LE, UK
Alzheimer's Research & Therapy 2009, 1:3 doi:10.1186/alzrt3
Published: 9 July 2009Abstract
The pathology of Alzheimer's disease (AD) features amyloid β peptide deposition, intracellular neurofibrillary tangles and deficits in the cholinergic pathway. Abnormal blood pressure is recognised as a risk factor for the development of AD, although the underlying mechanisms remain unproven. This review proposes angiotensins and associated enzymatic pathways as important mediators of recognised but undefined links between blood pressure and AD. Evidence in support of this involvement translates consistently from the most basic in vitro, in vivo and ex vivo experimental paradigms to more complex human-based observational and experimental studies, which also fortunately offer potential for therapeutic interventions against AD.